Medical Costs and Quality of Life 10 to 12 Years After Randomization to Angioplasty or Bypass Surgery for Multivessel Coronary Artery Disease

• DOI: 10.1161/01.cir.0000143379.26342.5c
• Publication Date: 2004-09-28T00:14:19Z
• Authors: Mark A. Hlatky; Derek B. Boothroyd; Kathryn A. Melsop; Maria M. Brooks; Daniel B. Mark; Bertram Pitt; Guy S. Reeder; William J. Rogers; Thomas J. Ryan; Patrick L. Whitlow; Robert D. Wiens
• Keywords: Employment; Male; Cost-Benefit Analysis; Graft Survival; Coronary Disease; Comorbidity; Health Care Costs; Middle Aged; Angina Pectoris; 3. Good health; Coronary Restenosis; 03 medical and health sciences; 0302 clinical medicine; Disease Progression; Quality of Life; Humans; Female; Prospective Studies; Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Aged; Follow-Up Studies; Randomized Controlled Trials as Topic

Background—

Coronary bypass surgery (CABG) and angioplasty (PTCA) have been compared in several randomized trials, but data about long-term economic and quality-of-life outcomes are limited.

Methods and Results—

Cost and quality-of-life data were collected prospectively from 934 patients who were randomized in the Bypass Angioplasty Revascularization Investigation (BARI) and followed up for 10 to12 years. CABG had 53% higher costs initially, but the gap closed to <5% during the first 2 years; after 12 years, the mean cumulative cost of CABG patients was $123 000 versus $120 750 for PTCA, yielding a cost-effectiveness ratio of $14 300/life-year added. CABG patients experienced significantly greater improvement in their physical functioning for the first 3 years but not in later follow-up. Recurrent angina substantially reduced all quality-of-life measures throughout follow-up. Cumulative costs were significantly higher among patients with diabetes, heart failure, and comorbid conditions and among women; costs also were increased by angina, by the number of revascularization procedures, and among patients who died.

Conclusion—

Early differences between CABG and PTCA in costs and quality of life were no longer significant at 10 to 12 years of follow-up. CABG was cost-effective as compared with PTCA for multivessel disease.